Icon (ICLR) Cash from Financing Activities (2009 - 2026)
Icon's (ICLR) quarterly Cash from Financing Activities came in at -$8.1 million in Q2 2026, up 96.83% year-over-year from -$4.1 million in Q2 2025, and down 27.65% quarter-over-quarter from -$6.4 million in Q1 2026.
Analysis
Icon (ICLR) Cash from Financing Activities (2009 - 2026) Analysis & Trends
Icon (ICLR) has reported Cash from Financing Activities for 18 consecutive years, with -$8.1 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash from Financing Activities rose 96.83% year-over-year to -$8.1 million in Q2 2026; TTM through Jun 2026 was -$319.0 million, a 69.85% increase from a year earlier, with the FY2025 full-year figure at -$813.2 million, up 8.1% from the prior year.
- Cash from Financing Activities was -$8.1 million for Q2 2026 at Icon, down from -$6.4 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at -$6.4 million in Q1 2026 and troughed at -$451.7 million in Q4 2024.
- A 5-year average of -$190.0 million and a median of -$189.7 million in 2022 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities slumped 53792.44% in 2022 and jumped 97.49% in 2026, its largest moves.
- Over 5 years, Cash from Financing Activities stood at -$193.1 million in 2022, then sank by 32.31% to -$255.5 million in 2023, then slumped by 76.75% to -$451.7 million in 2024, then soared by 89.42% to -$47.8 million in 2025, then jumped by 83.01% to -$8.1 million in 2026.
- The last three Cash from Financing Activities figures came in at -$8.1 million (Q2 2026), -$6.4 million (Q1 2026), and -$47.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn | -214.00 Mn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn | -288.34 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn | -8.12 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn | -164.66 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn | - |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn | 16.49 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn | 33,000.00 |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn | 248,151.59 |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - | -118,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -8.12 Mn |
| Mar 31, 2026 | -6.36 Mn |
| Dec 31, 2025 | -47.78 Mn |
| Sep 30, 2025 | -256.77 Mn |
| Jun 30, 2025 | -255.86 Mn |
| Mar 31, 2025 | -252.83 Mn |
| Dec 31, 2024 | -451.69 Mn |
| Sep 30, 2024 | -97.78 Mn |
| Jun 30, 2024 | -71.75 Mn |
| Mar 31, 2024 | -263.70 Mn |
| Dec 31, 2023 | -255.55 Mn |
| Sep 30, 2023 | -258.67 Mn |
| Jun 30, 2023 | -172.77 Mn |
| Mar 31, 2023 | -157.06 Mn |
| Dec 31, 2022 | -193.14 Mn |
| Sep 30, 2022 | -186.17 Mn |
| Jun 30, 2022 | -92.35 Mn |
| Mar 31, 2022 | -392.51 Mn |
| Dec 31, 2021 | -485.47 Mn |
| Sep 30, 2021 | 5.60 Bn |